Tenders

Medicines with the Active Ingredient Ustekinumab (Atc: L04ac05)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Albendazole, Atc P02ca03 (Obg) for the Period August 1St, 2024 - July 31St, 2026

Medicines with the Active Ingredient Lanthanum (Iii) Carbonate (Atc: V03ae03 - in the Dosage Form Chewable Tablets)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Naloxegol, Atc A06ah03 (Obo) for the Period August 1St, 2024 - July 31St, 2026

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Pomalidomide, Atc L04ax06 (Obg) for the Period August 1St, 2024 - July 31St, 2026

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Colistin, Atc J01xb01 (Obg) for the Period August 1St, 2024 - July 31St, 2026

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Ustekinumab, Atc L04ac05 (Obo) for the Period August 1St, 2024 - July 31St, 2025 (Plus Extension Option 1X12 Months)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Bimatoprost + Timolol (Exclusively Edo), Atc S01ed62 (Obo) for the Period August 1St, 2024 - July 31St, 2026

Open House Drug Discount Agreements Ustekinumab, Atc L04ac05

Medicines with the Active Ingredient Guselkumab (Atc: L04ac16)